Study Design. A retrospective study of 180 patients with lung cancer spinal metastases, wherein prognostic score-predicted survival was compared with actual survival. Objective. To evaluate and compare the accuracy of prognostic scoring systems in lung cancer spinal metastases. Summary Of Background Data. The modified Tokuhashi, Tomita, modified Bauer, and Oswestry scores are currently used to guide decisions regarding operative treatment of patients with spinal metastases. The best system for predicting survival in patients with lung cancer spinal metastases remains undetermined. The high incidence of spinal metastases from lung cancer and improved survival of patients treated with systemic therapy warrants evaluation of these scoring systems in this particular context. Methods. Patients with lung cancer spinal metastases treated at our institution between May 2001 and August 2012 were studied. Fifty-one patients were treated surgically. The primary outcome measure was survival from the time of diagnosis. Scoringpredicted survival was compared with actual survival. Potential prognostic factors were investigated using Cox regression analyses. Predictive values of each scoring system for 3-and 6-month survival were measured via receiver operating characteristic (ROC) curves. Results. Histological subtype (P ¼ 0.015), sex (P ¼ 0.001), Karnofsky performance scale (P ¼ 0.001), extent of neurological palsy (P ¼ 0.002), and visceral metastases (P ¼ 0.037) are significant predictors of survival. Besides the Oswestry spinal risk index, no significant differences were found between different prognostic subgroups within the individual scoring systems. Although the modified Bauer score was most accurate, all four scoring systems had areas under the ROC curve 0.5 or less. Conclusion. Although better prognostic scores correlated with longer survival, all four scoring systems are inaccurate in prognosticating patients with lung cancer spinal metastases. Specific lung cancer histology appears prognostic and should be considered, especially given the increased survival of patients receiving new targeted therapies appropriate to their disease.
L ung cancer is the most common cancer worldwide, with an estimated 1.8 million new diagnoses each year, 1 whereas the spine is a common site of metastases, with lung cancer being one of the most common primaries responsible. 2, 3 Spinal metastases are associated with a decreased quality of life and increased mortality; with complications including cord compression, pathological fractures, and spinal instability. [4] [5] [6] [7] Treatment options include chemotherapy, radiotherapy, and surgery; however, potential complications and high costs limit its indication to patients who can be expected to survive long enough to benefit from surgery. Whereas some studies advocate a life expectancy greater than 3 months as a cutoff for surgery, 8, 9 others advocate at least 6 months. 10 Since the randomized control trial by Patchell et al. 11 demonstrated the superiority of surgery with adjuvant radiotherapy over radiotherapy alone, an increase in surgical treatment of spinal metastases has been observed. systems such as the modified Tokuhashi, 13 Tomita, 14 modified Bauer, 10 and Oswestry scores 15 have been devised to guide the management of these patients; however, there is currently no consensus on the most accurate score for prognosticating survival in patients with spinal metastases from primary lung cancer. The use of molecular targeted therapy has also improved progression-free survival in patients with advanced stage non-small cell lung cancer (NSCLC) harboring sensitizing mutations in the epidermal growth factor receptor (EGFR) gene. 16, 17 This may affect the validity of these existing scoring systems, which were devised before EGFR targeted therapy was available. Hence, we aim to characterize prognostic factors of patients with lung cancer spinal metastases, and to evaluate the robustness of these prognostic-scoring systems.
MATERIALS AND METHODS

Patient and Data Collection
We retrospectively analyzed all patients with histologically confirmed lung cancer treated for spinal metastases at our institution between May 2001 and April 2012. To avoid selection bias, electronic diagnostic codes were used to identify patients regardless of whether they had been referred to the spinal unit. A total of 190 patients were identified in this period. Ten patients were excluded as they had either incomplete clinical/radiological investigations, or were lost to follow-up with time of death unknown. Actual survival data were available for the remaining 180 patients from the National Registry of Diseases Office. Spinal metastases were diagnosed radiologically by one or more of the following modalities: magnetic resonance imaging, computed tomography, and nuclear bone scans. In some cases, bone biopsy was also procured. Patient data collected included demographic characteristics, tumor histology, (including EGFR mutation status), and clinical findings in relationship to the primary tumor and skeletal metastases. Clinical findings were recorded at the time of diagnosis of spinal metastases, and included the Karnofsky Performance Scale, number of extraspinal bone metastases, number of vertebral bone metastases, number of visceral metastases, and neurologic assessment based on the Frankel score. These were used to calculate the modified Tokuhashi, Tomita, modified Bauer, and Oswestry scores. Patients with incomplete data were excluded from the study if their scores were not calculable. The scores were independently calculated by the first and second authors, who were blinded from the patients' identity and actual survival. Any score discrepancy, was reevaluated by the senior author, and a consensus score was assigned. Sub-analyses for the influence of age, sex, ethnicity, and EGFR tyrosine kinase inhibitor (TKI) therapy were performed.
Statistical Analysis
Univariate and stepwise multivariate Cox regression analyses were used to evaluate the influence of each demographic and clinical parameter on survival. Cox regression analyses were carried out for all scoring systems. Predictive values of each scoring system (for 3-and 6-month survival) were measured by building receiver operating characteristic (ROC) curves via postestimation commands following Cox regression analyses. ''C'' statistics were used to compare the area under the receiver operating characteristic (AUCROC) curves for each scoring system. Statistical significance was defined as P < 0.05 throughout the study, and all analyses were performed with Stata Statistical software v.12 (StataCorp LP, College Station, Texas, USA).
RESULTS
A total of 180 patients were included in the final analysis. Of these, 51 underwent operative treatment, whereas 129 were treated nonoperatively. Fifty (27.8%) patients received EGFR TKI therapy. The median age was 63 (range: 33-93) years, and 58.9% of patients were male. Eighteen (10%) patients were diagnosed with small-cell lung cancer (SCLC), whereas 162 (90%) had NSCLC. Only 56 (31.1%) patients had good Karnofsky performance scores, whereas 124 (68.9%) had moderate or poor Karnofsky performance scores. Eighty-six (47.8%) patients had visceral metastases and 85 (47.2%) had evidence of neurological compromise secondary to spinal metastases. The distribution of patients' demographic characteristics, treatment approaches, and clinical parameters are summarized in Table 1 .
The prognostic values of specific clinical parameters according to univariate and multivariate Cox-regression analysis are shown in Table 2 . Univariate analysis revealed that sex, histology, presence of visceral metastases, general condition, neurological palsy, Frankel score, and EGFR TKI therapy had significant effects on survival. Multivariate analysis revealed that male gender (P < 0.01) and histological diagnosis of small-cell lung cancer (SCLC) (P ¼ 0.02) were poor prognostic factors, whereas absence of visceral metastases (P < 0.01), good Karnofsky performance score (P < 0.01), and absence of neurological palsy (P < 0.01) were prognostically favorable. EGFR TKI therapy was no longer predictive of survival on multivariate analysis.
Survival
The overall median survival time was 4. 
Modified Tokuhashi Score
The median modified Tokuhashi score was 5 (range: 1-10). Only 75 of 180 patients (41.7%) had a predicted survival that correlated with their actual survival. Although only 11 (6.1%) patients were predicted to survive more than 6 months, 80 (44.4%) of them did so.
Tomita Score
The median Tomita score was 8 (range: 6-10), and 94 of 180 (52.2%) patients had scores of 8 to 10, translating to less than 3 months predicted survival. In contrast, 111 of 180 (61.7%) patients survived for more than 3 months.
Modified Bauer Score
The median modified Bauer score was 1 (range: 0-2), and 169 of 180 (93.9%) patients had scores of 0 to 1, predicting median survivals of 4.8 months. Although this is reflective of the actual median survival of our cohort (4.8 months), only 58 of 180 (32.2%) patients had actual survival that correlated with predicted survival.
Oswestry Spinal Risk Index
110/180 (61.1%) patients had an actual survival that correlated with predicted survival. The median Oswestry spinal risk index (OSRI) of 6 (range: 5-7) predicted a median survival of 2 months, whereas actual median survival in our cohort was 4.8 months.
Evaluation of the Scoring Systems
Cox regression analyses revealed that the absolute score of all scoring systems were significantly associated with the actual survival in all patients. Higher scores in the modified Tokuhashi (P < 0.01) and modified Bauer (P < 0.01) scoring systems were associated with longer survival, whereas higher scores in Tomita (P < 0.01) and Oswestry (P < 0.01) scoring systems were associated with poorer survival. Each scoring system classifies patients into different prognostic sub-groups based on their scores. There was no statistically significant difference between sub-groups of the modified Tokuhashi, Tomita, and modified Bauer scores. Only the OSRI showed significant differences in actual survival between its different predicted survival groups (Table 3) .
Predictive Values of the Scoring Systems
The predictive abilities of each scoring system as measured by ROC curves at 3-and 6-month survival are presented in Table 4 . All 4 scoring systems have AUCROC scores 0.5 or less for both 3-and 6-month survival. The modified Bauer score was the most accurate with an AUCROC of 0.48 and 0.50 for 3-and 6-month survival, respectively.
DISCUSSION
The survival of patients with lung cancer spinal metastases has significantly improved within the past 10 years. Morgen et al. 
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The most accurate prognostic scoring system for these patients still remains undetermined. The modified Tokuhashi score 13 has cohort studies supporting its utility in patients with mixed groups of primary tumors, [19] [20] [21] [22] but its reliability in lung cancer spinal metastases remains less certain. Hessler et al. 18 and Majeed et al. 23 have shown correlation between the Tokuhashi score and actual survival in lung cancer, whereas Wang et al. 19 and Ogihara et al. 24 failed to demonstrate any significant predictive value of the Tokuhashi score. Likewise, Gakhar et al. 25 reported a modified Tokuhashi accuracy rate of 44% for their lung cancer sub-group. The Tomita score 14 has been shown to be of modest prognostic value in studies with a mixed group of primary tumors 2 but has not been specifically validated in lung cancer. Leithner et al. 10 and Wibmer et al. 26 compared different scoring systems and found the modified Bauer score to be the best in predicting survival in patients with spinal metastases. The OSRI combines the patients' general condition with tumor histology, 15 and has been validated by Whitehouse et al. 27 and Fleming et al. 28 Therefore, our study serves to fill the gaps in existing literature, which either attempt to validate these scores in patients with spinal metastases of heterogeneous primaries, or do not compare the accuracy of the different scoring systems when looking at spinal metastases from the same primary tumor type. To eliminate selection bias, our study included lung cancer patients who have been managed both surgically and nonsurgically.
Our study showed that in all four scoring systems, better scores correlated with better survival; however, with the exception of the OSRI, there was no significant difference in survival between the prognostic subgroups in each of the other three scoring systems. In addition, the predicted survival given by the prognostic subgroups correlated poorly with actual survival. For all four scores, the AUCROC at 3-and 6-months was 0.5 or less. An AUCROC 0.5 or less suggests a failed test, wherein the accuracy of the score is equivocal or misleading. In our study, all four scoring systems underestimated overall survival, indicating that it is inappropriate to utilize these scores to guide clinical decisions in managing these patients.
Sex (female better than male), tumor histology (NSCLC better than SCLC), general condition, visceral metastases, and neurological palsy were shown to be significant predictors of actual survival upon multivariate analysis. The importance of general condition and visceral metastases in predicting the survival of lung cancer spinal metastases patients has been previously described. [29] [30] [31] The absence of neurological palsy and the ability to ambulate have been described previously as good prognostic factors. 31 NSCLC patients had significantly better survival (P ¼ 0.02) than SCLC patients. In addition to inherent biological differences between NSCLC and SCLC, this may reflect advances in the systemic treatment of NSCLC. The advent of the small-molecule EGFR TKIs that competitively inhibit EGFR cellular pathways, has led to an increase in progression-free survival in patients with EGFR mutations. 32, 33 EGFR TKI therapy is now used in the first-line treatment of patients with advanced stage NSCLC harboring sensitizing EGFR mutations. 16, [34] [35] [36] Our study group showed EGFR TKI therapy to be predictive of improved survival on univariate analysis, but not on multivariate analysis. EGFR mutation testing was only initiated at our institution in 2008, and was not routine until the later years of our study period, resulting in a small sample size with regards to this variable. Failure of the impact of EGFR TKI therapy to reach statistical significance during multivariate analysis could be attributable to the fact that 34 (64%) of the patients treated with it were not confirmed EGFR mutation positive prior to initiation of treatment, and were treated empirically. We hypothesize that this may have led to a mismatch between indication for and administration of EGFR TKI treatment to this group of patients.
In this study, we found male gender had a worse survival than female patients. Our patient population group was composed predominantly of East Asian descent, and female patients of East Asian descent with adenocarcinoma are more likely to be responsive to EGFR TKIs. 1, 35, 36 This could explain why male patients had poorer survival than female patients. Furthermore, in NSCLC, it is also well recognized that females have a better prognosis than males. 37, 38 Current predictive systems are inaccurate in prognosticating survival and should not be used in guiding clinical decisions in these patients. The findings suggest that patients should be evaluated on a case-by-case basis, taking into account the following prognostic factors: tumor histology, sex, presence of visceral metastases, general condition (as defined by the Karnofsky performance scale), and presence of neurological palsy (as defined by the Frankel Scale). Histological subtype (NSCLC vs. SCLC), and sensitivity to EGFR TKIs should be considered in addition to the above prognostic factors when formulating future prognostic scoring systems. Gregory et al. 39 have similarly highlighted the importance of considering the effect of newer molecular targeted agents when prognosticating patients with spinal metastases.
No significant difference in survival was found in this retrospective cohort between cases managed surgically and nonsurgically (P ¼ 0.43); however, no inferences about the effect of surgery on survival can be drawn, as this was not analyzed using multivariate analyses with adjustment for potentially confounding variables.
Strengths and Limitations
This study focuses on cases of spinal metastases from primary lung cancer, thus reducing tumor-specific confounding effects during direct comparison of all four scoring systems. The relatively large cohorts, along with the inclusion of both surgically and nonsurgically managed patients are additional strengths. The retrospective study design is a limitation, due to heterogeneity in treatment and investigation protocols over the study period, as the period of data collection crossed the point at which targeted therapy emerged. Insufficient sample size precluded the investigation of survival differences between certain prognostic subgroups within individual scoring systems.
CONCLUSION
All four prognostic systems evaluated in our study were inaccurate and if used should be interpreted with caution in prognosticating lung cancer patients with spinal metastases. Newer prognostication systems should incorporate histological subtype and responsiveness to EGFR TKIs and other targeted therapies. We recommend that decisions regarding surgical management of such patients should be made on a case-by-case basis, relying on the surgeon's clinical judgment and the multidisciplinary team's opinion rather than on existing prognostic scores. This would promote more objective surgical decision-making, and better complement advancements in oncologic treatment.
Key Points
Current prognostic scoring systems are inaccurate in prognosticating lung cancer patients with spinal metastases and should be interpreted with caution. Newer scoring systems should account for increased survival gained from new targeted therapies.
The decision for surgical management should be reviewed on a case-by-case basis, with consideration of histological subtype, sex, general condition, presence of neurological palsy, and visceral metastases.
